Myriad Genetics Inc
NASDAQ:MYGN
Myriad Genetics Inc
Nestled at the crossroads of healthcare innovation and genetic science, Myriad Genetics Inc. has been a pioneering force in molecular diagnostics for over three decades. Founded in 1991 and headquartered in Salt Lake City, Utah, the company carved out its niche by focusing on predictive medicine—an area that seeks to forecast disease risk based on genetic predispositions. At the heart of Myriad's operations is its robust arsenal of genetic tests that identify individuals' risk for various conditions, including cancer, cardiovascular illnesses, and other hereditary disorders. This approach not only aids early intervention and personalized treatment plans but also empowers patients with crucial information about their genetic backgrounds.
Myriad's business model orbits around the research, development, and commercialization of these high-impact diagnostic tests. Revenue streams flow primarily from the sale of its flagship products, which include the BRACAnalysis CDx test for assessing breast and ovarian cancer risk and various other hereditary cancer tests that evaluate susceptibility to prostate and colorectal cancers. Further, Myriad advances its impact through collaborations with healthcare providers, folding clinical research findings into broader medical practice. In a world where healthcare is increasingly leaning towards precision medicine, Myriad Genetics stands as a testament to the value of science-led business strategies, sustaining its growth through a clear focus on marrying advanced genomic knowledge with accessible and actionable clinical applications.
Nestled at the crossroads of healthcare innovation and genetic science, Myriad Genetics Inc. has been a pioneering force in molecular diagnostics for over three decades. Founded in 1991 and headquartered in Salt Lake City, Utah, the company carved out its niche by focusing on predictive medicine—an area that seeks to forecast disease risk based on genetic predispositions. At the heart of Myriad's operations is its robust arsenal of genetic tests that identify individuals' risk for various conditions, including cancer, cardiovascular illnesses, and other hereditary disorders. This approach not only aids early intervention and personalized treatment plans but also empowers patients with crucial information about their genetic backgrounds.
Myriad's business model orbits around the research, development, and commercialization of these high-impact diagnostic tests. Revenue streams flow primarily from the sale of its flagship products, which include the BRACAnalysis CDx test for assessing breast and ovarian cancer risk and various other hereditary cancer tests that evaluate susceptibility to prostate and colorectal cancers. Further, Myriad advances its impact through collaborations with healthcare providers, folding clinical research findings into broader medical practice. In a world where healthcare is increasingly leaning towards precision medicine, Myriad Genetics stands as a testament to the value of science-led business strategies, sustaining its growth through a clear focus on marrying advanced genomic knowledge with accessible and actionable clinical applications.
Revenue: Myriad Genetics reported Q3 2025 revenue of $205.7 million, down 4% year-over-year, but underlying growth was 5% after adjusting for headwinds.
Volume Growth: Test volumes rose 3% overall, with strong hereditary cancer (MyRisk) volume up 11% and mental health (GeneSight) volume up 8% year-over-year.
Profitability: Adjusted gross margin was 70.1%, and adjusted EBITDA reached $10.3 million, reflecting operational discipline.
Guidance Reaffirmed: Full-year 2025 guidance for revenue ($818–828 million), gross margin (69.5–70%), and adjusted EBITDA ($27–33 million) was reaffirmed.
Strategic Focus: Management emphasized a new strategy centered on the cancer care continuum, with increased investment in commercial capabilities and R&D for oncology.
Product Pipeline: Launch of expanded MyRisk panel is slated for November, and the combined AI-enabled Prolaris test and Precise MRD test are on track for 2026.
Operational Changes: The company is reallocating resources, expanding its sales team, and aiming to grow revenue faster than operating expenses.
Payor & Market Dynamics: The company is securing new state biomarker law coverage for GeneSight but continues to face pressure from UnitedHealthcare’s GeneSight policy.
